On March 9, 2022 IN3BIO Research Limited, a leader in developing cancer treatments that, based upon clinical data, show significant promise and appear to be more tolerable for patients, reported that it has received Clinical Trial Application approval from the British Medicines & Healthcare Products Regulatory Agency (MHRA) to initiate a Phase I/II clinical trial of its colorectal cancer vaccine (Press release, In3Bio, MAR 9, 2022, View Source [SID1234609850]). This is the company’s second global regulatory approval for the trial, having obtained approval to conduct the study in Bulgaria earlier this year.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With these approvals, IN3BIO is one step closer to bringing its innovative cancer treatments to market. The company is in the process of a Series A financing round for the Phase I/II trial as well as for developing a second molecule to advance its global mission.